Project Number 5P50AG005131-35 Agency/Funding Organization NIA Funding Year 2018 View Full Project Details for Clinical Core Research Categorization Primary Disease / Condition Multiple Dementias CADRO Category F. Research Resources 1. Alzheimer's Disease Centers Researcher and Organization Principal Investigator GALASKO, DOUGLAS R Principal Investigator First Name DOUGLAS Principal Investigator Last Name GALASKO Awardee Organization UNIVERSITY OF CALIFORNIA SAN DIEGO Awardee State California Contact PI Country United States Project Detail Funding Opportunity Announcement RFA-AG-13-019: Alzheimer's Disease Research Centers (P50) FY Overall Cost $974,231 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official SILVERBERG, NINA B Related Resources Repository [AlzPED] CRF receptor-1 antagonism mitigates Aβ pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease [AlzPED] Peptides of presenilin-1 bind the amyloid precursor protein ectodomain and offer a novel and specific therapeutic approach to reduce ß-amyloid in Alzheimer's disease [AlzPED] Novel therapeutic strategy for neurodegeneration by blocking Aβ seeding mediated aggregation in models of Alzheimer's disease. [AlzPED] Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models. [AlzPED] A Neuroprotective Brain-penetrating Endopeptidase Fusion Protein Ameliorates Alzheimer Disease Pathology and Restores Neurogenesis [AlzPED] Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice. [AlzPED] Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. [AlzPED] Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. [AlzPED] Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin. [AlzPED] The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. Pagination Previous page ‹‹ Page 2
